MIL:BB (Switzerland)
Â
CE with IsEquityFundamentalDataAvailable = 1 in Gid
€
65.20
(0%)
Sep 27
Business Description
BB Biotech AG
NAICS : 325414
ISIN : CH0038389992
Share Class Description:
MIL:BB: CE with IsEquityFundamentalDataAvailable = 1 in GidDescription
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 6/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year FCF Growth Rate | -5.6 | |||||
| 3-Year Book Growth Rate | -15.5 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Payout Ratio | 0.47 | |||||
| 3-Year Average Share Buyback Ratio | 0.3 | |||||
| Shareholder Yield % | 0.56 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Net Margin % | 92.4 | |||||
| FCF Margin % | 40.94 | |||||
| ROE % | 10.04 | |||||
| ROA % | 8.82 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 9.4 | |||||
| Forward PE Ratio | 20.22 | |||||
| PE Ratio without NRI | 9.4 | |||||
| Shiller PE Ratio | 4.95 | |||||
| PS Ratio | 8.68 | |||||
| PB Ratio | 0.92 | |||||
| Price-to-Tangible-Book | 0.92 | |||||
| Price-to-Free-Cash-Flow | 20.92 | |||||
| Price-to-Operating-Cash-Flow | 20.92 | |||||
| EV-to-Revenue | 9.24 | |||||
| EV-to-FCF | 22.4 | |||||
| Price-to-Projected-FCF | 0.73 | |||||
| Price-to-Graham-Number | 0.62 | |||||
| FCF Yield % | 5.17 | |||||
| Forward Rate of Return (Yacktman) % | 13.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BB Biotech AG Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 264.562 | ||
| EPS (TTM) (€) | 4.438 | ||
| Beta | 0 | ||
| Volatility % | 3.15 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 65.2 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 65.2 - 65.2 | ||
| Shares Outstanding (Mil) | 54.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BB Biotech AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BB Biotech AG Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
BB Biotech AG Frequently Asked Questions
What is BB Biotech AG(MIL:BB)'s stock price today?
The current price of MIL:BB is €65.20. The 52 week high of MIL:BB is €65.20 and 52 week low is €65.20.
When is next earnings date of BB Biotech AG(MIL:BB)?
The next earnings date of BB Biotech AG(MIL:BB) is 2024-10-18 Est..
Does BB Biotech AG(MIL:BB) pay dividends? If so, how much?
BB Biotech AG(MIL:BB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers